Chris Anzalone, Arrowhead CEO
June 27, 2022 11:12 AM EDTUpdated June 28, 10:01 AM
R&D

Take­da, Ar­row­head spot­light da­ta from small tri­al show­ing RNAi works in a rare liv­er con­di­tion

Amber Tong

Al­most two years af­ter Take­da wa­gered $300 mil­lion cash to part­ner with Ar­row­head on an RNAi ther­a­py for a rare dis­ease, the com­pa­nies are spelling …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times